Who is sponsoring RELATIVITY-127?

RELATIVITY-127 is sponsored by Bristol-Myers Squibb.

What condition does RELATIVITY-127 study?

RELATIVITY-127 studies Melanoma.

What drugs are being tested in RELATIVITY-127?

Interventions: Nivolumab + Relatlimab, rHuPH20.

What is the status of RELATIVITY-127?

RELATIVITY-127 is currently ACTIVE_NOT_RECRUITING.

Last reviewed 2025-08-24 · How we verify

A Study of Subcutaneous Nivolumab + Relatlimab Fixed-dose Combination (FDC) in Previously Untreated Metastatic or Unresectable Melanoma (RELATIVITY-127)

NCT05625399 PHASE3 ACTIVE_NOT_RECRUITING

The purpose of this study is to demonstrate that the study drug exposure level of the nivolumab + relatlimab FDC subcutaneous (SC) formulation is not worse than nivolumab + relatlimab FDC intravenous (IV) administration in participants with previously untreated metastatic or unresectable melanoma.

Details

Lead sponsor	Bristol-Myers Squibb
Phase	PHASE3
Status	ACTIVE_NOT_RECRUITING
Enrolment	579
Start date	Mon Mar 06 2023 00:00:00 GMT+0000 (Coordinated Universal Time)
Completion	Thu Nov 18 2027 00:00:00 GMT+0000 (Coordinated Universal Time)

Conditions

Melanoma

Interventions

Nivolumab + Relatlimab
rHuPH20

Countries

Italy, Finland, Poland, Belgium, Sweden, United States, France, Austria, Chile, Israel, Norway, Canada, Spain, Brazil, United Kingdom, Germany, Switzerland, Australia, Czechia